It remains to be seen how much GlaxoSmithKline's China bribery scandal will cost the British pharma, but it has already cost CEO Andrew Witty up to $410,000 in potential bonus money, according to the company's annual report.
When GlaxoSmithKline launched respiratory med Breo, media reports buzzed over the company's emphasis on the treatment's risks. But as GSK spokesman Juan Carlos Molina told FiercePharmaMarketing, hammering home risks--as well as benefits--is not necessarily something new for Glaxo.
European regulatory authorities gave Teva a positive opinion for its DuoResp Spiromax inhalation powder, designed to treat asthma and chronic obstructive pulmonary disease. With the recommendation from the Committee for Medicinal Products for Human Use, Teva hopes to have final approval within a few months.
A European Medicines Agency committee has recommended approval for another COPD treatment from GlaxoSmithKline, setting the stage for a likely nod in the coming months as the drugmaker looks to bolster its respiratory franchise.
China has yet to leverage any formal penalties on GlaxoSmithKline for the $489 million bribery scandal that broke there last summer. But punishment may be on the way from GSK's home base.
While it's still unclear how long copycats will take to make a serious dent in GlaxoSmithKline's respiratory franchise once generic competition inevitably erodes sales of the $8.8 billion-selling Advair, Glaxo may soon have a new building block with European regulators' new recommendation for combo med Anoro.
GlaxoSmithKline's lung drug Anoro Ellipta, key to rebuilding its respiratory franchise after megablockbuster Advair meets generic competition, won approval from European authorities.
GlaxoSmithKline says it's worried about adequate regulation for e-cigarettes, and it's pushing Europe to require more. After all, more red tape to cut through for e-cigarette makers can't hurt the British pharma giant, which competes against them directly with its Nicorette gum and other quit-smoking products.
According to the latest survey from PatientView, in the healthcare industry, multinational pharma companies rank next to last, reputation-wise. Biotech companies come in just above that. Since 2011, pharma's reputation, already not so hot, has slipped even further.
GlaxoSmithKline is looking to deepen its respiratory pipeline with another late-stage trial of the injectable mepolizumab, this time studying the drug's effects in a rare inflammatory disease that can be life-threatening.